0755-82943241 Email:zhangmf@ccs.com.cn 002038 2004 9 8 12 15 12 19.23 2003H 2004E 7105 9592 % 43 35 ( ) 4994 6738 % 32.1 34.9 3120 4022 % 61.7 28.9 0.45 0.58 6900 1900 10 4 80% 49.7% 28.5% 4 1 04 13.5 7 20 25 30 2003 0.45 9.0 11.3 13.5 2004E 0.58 11.6 14.5 17.4 1/12
1994 60% 4 G-CSF IL-2 rhbfgf IL-11 2003 1.52 1.15 24.2% 2003 7105 3119 27.1% 1 1 % 2250 32.61 500 7.26 225 3.26 125 1.81 1750 25.36 37.5 0.54 37.5 0.54 37.5 0.54 37.5 0.54 1900 27.54 6900 100 95% 5% 21202 7 2 2 11 2970 3 3700 6 3200 6 3600 4.5 2950 3.8 3500 4.6 3897 2/12
23817 2001 2003 49.7% 28.5% 84.9% 03 70.9% 2004 63.8% 02 03 02 2 02 13.4% 2 8000 7000 6000 5000 4000 3000 2000 1000 0 49.7% 36.7% 26.9% 2001 2002 2003 28.5% 90.00% 80.00% 70.00% 60.00% 50.00% 40.00% 30.00% 20.00% 10.00% 0.00% 85% 84% 77% 76% 71% 70% 64% 63% 65% 44% 47% 36% 60% 39% 44% 31% 2001 2002 2003 2004 02 3 3 2001 2002 2003 2004 5.1% 10.7% 8.8% 10.7% 15.5% 22% 16.3% 17.3% 0.19% 0.08 0.15% 0.05% 5.5 13.4 8.05 9.11 % 3/12
3 3 4000 3000 2000 1000 0 2001 2002 2003 2001 2003 04 04 4 2001 2002 2003 2004 NA 3.4 3.95 2.06 NA 4.62 3.16 1.89 NA NA 0.61 0.21 % 14.05 16.75 23.95 12.01 5.47 3.88 2.67 6.49 5.32 3.54 2.39 5.91 / % 66 67.6 88 74.3 4/12
GMP 150 2000 5 03 4 62.4% 02 5 6 5 % % rhg-csf 1322 89 18.6 (rhil-2) (rhbfgf) 1293 84 18.2 546 81 7.7 (rhil-11) 1271 85 17.9 1860 39 26.2 CTP 469 72 6.6 2003 6 2002 ()/ 1998-06 50 20% 2 1999-03 80 31% 2 2002-05 80 112003-03 20 CTP 2002-2003 1000 CTP 6 2003-03 1000 03 5/12
03 19.3 02 03 22 CTP03 4 5 4 2000 1500 12.7% 2.3% 8.6% 1000 64.8% 75.1% 500 0 CTP 2001 1734 1235 201 2002 1704 1360 172 1577 153 2003 1322 1292 546 1272 1860 469 343 2001 2002 2003 5 100.00% 80.00% 60.00% 40.00% 20.00% 0.00% CTP 2001 90.10% 81.30% 63.10% 2002 91% 81.10% 61.40% 61.20% 59.90% 2003 89% 84.50% 80.70% 84.80% 39.20% 71.80% 200488.90% 85.80% 67.80% 82% 32.60% 56.90% 2001 2002 2003 2004 10 4 rhg-csf1991 Amgen FDA 6/12
2002 20 2000 21 2001 17 2002 15 1998 N 30% 75g100g 150g200g 300g 5 rhg-csf 7 20 80 7 rhg-csf 1998 75g/ 2000 75g/ 150g/ 300g/ 1999 75g/ 1999 150g/ 1999 300g/ 1999 300g/ 150g/ 75g/ 1999 300g/ 150g/ 75g/ 1999 1998 1998 1998 1998 75g/ 150g/ 300g/ 2001 75g/ 150g/ 300g/ 2001 75g/ 2001 75g/ 150g/ 300g/ 2001 100g/ 200g/ 480g/ 2003 200g/ 2003 2125Ala IL-2 1990 2 CETUS 1999 2 125 2 2 125 7/12
125Ser IL-2 125Ala IL-2 2000 2001 2 10 8 2004 2 2 8 2 2125Ala 1999 2000 2001 50 2004-2-2 IU/ 50 IU/ 2004-1-21 100 IU/ 4mg/ 2003-9-2 1997 2003-3-18 1997 1995 1996 1996 rhbfgf 2000 3 12 2002 5 92 9 S20040001 2004-1-8 S20040006/ S20040006 S-03 1997 S-01 1996 S-01S-02 8/12
1999 S-01 1999 S-01 1999 1999 11 rhil-111997 GI 2003 3 rhil-11 600 700 5~10 03 rhil-11 1272 84.8% rhil-11 rhil-11 1 2002 1 2002 1577 2003 61% 33% 10 10 2006 5~10 2007 3000 2007 9/12
2007 8000 3000 18 2005 12 2 2000 2007 8000 2004 10 2005 10 1999 7 2003 10 2005 6 04 5 5 23% 04 2006 12 2007 8000 1 10/12
5-HT 2004 5 12 FDA 2003 2003 3 2003 10 2004 4 1998 FDA Amgen 122 510 2004 35% 28.9% 9592 4022 11 2025 1215 11 Hist 31-Dec-03 Proj 31_Dec-04 7105.08 9591.86 2064.67 2791.23 46.29 62.35 11/12
4994.12 6738.28 98.91 98.90 624.44 1055.10 1158.55 1659.39-10.99-140.96 3321.03 4263.64 0.00 0.00 0.00 0.00 0.00 0.00 18.64 0.00 3302.39 4263.64 182.59 242.17-0.20-0.20 3120.00 4021.67 6900 0.45 0.58 6 20% 6 10%--20% 6 6 10% A B C 12/12